Organizations Filed Purposes:
Our mission is to build a unique institute that bridges basic research and drug discovery, and that attracts the best and brightest scientists, physicians and students to work together synergistically to find cures for neglected human diseases. The California Institute for Biomedical Research (CALIBR) is a biomedical research organization located in San Diego, California. CALIBR bridges the gap between basic biomedical research and the clinical application of research discoveries to human disease. CALIBR commits substantially all of its resources to biomedical research activities. CALIBR's research and work will catalyze the translation of discoveries by scientists at other San Diego research institutes, as well as other major research institutes throughout the world, into potential new therapies for many life threatening and debilitating diseases. These diseases include orphan diseases, degenerative diseases of aging, cancer, autoimmune diseases, and infectious diseases.
The California Institute for Biomedical Research (CALIBR) accelerates the translation of basic biomedical research to new medicines for unmet medical needs.
Research grants and contracts are received from public and private institutions and are used to conduct biomedical research. In the current fiscal year, CALIBR conducted research through a private collaboration agreement on autoimmune and inflammatory diseases, cancer biology, cardiovascular metabolic diseases and neurobiology. In addition, it conducted research for the treatment of spinal muscular atrophy, juvenile diabetes, tb drug development, osteoarthritis, cryptosporidiosis and malaria.
Executives Listed on Filing
Total Salary includes financial earnings, benefits, and all related organization earnings listed on tax filing
| Name | Title | Hours Per Week | Total Salary |
|---|
| Leonardo Sahelijo | VP, Translational Medicine | 40 | $365,208 |
| Vadim Klyushnichenko | VP of Pharm. Dev & Quality | 40 | $314,321 |
| Peter G Schultz | CEO/President & Chair | 40 | $285,562 |
| Arnab K Chatterjee | VP, Medicinal Chemistry | 40 | $234,592 |
| John A Wisler | VP, Toxicology and Pharmacokinetics | 40 | $225,104 |
| Matthew S Tremblay | COO,CALIBR/Secretary (End 3/28/18) | 40 | $216,426 |
| Jing Li | VP, Program Management | 40 | $216,149 |
| Kelly San George End 32818 | CFO, CALIBR/Treasurer | 40 | $67,786 |
| Tamara L Barnas | Asst Secretary | 0 | $0 |
| Jared M Machado | CFO,Scripps/Treasurer | 1 | $0 |
| Douglas A Bingham | Secretary/EVP of Scripps Florida | 1 | $0 |
| Christopher T Walsh | Board Member | 1 | $0 |
| Paul R Schimmel End 92818 | Board Member | 1 | $0 |
| Bernard Saint-Donat Phd | Board Member (Start 3/28/18) | 1 | $0 |
| Mark Pearson Start 32818 | Board Member | 1 | $0 |
| John Martin Start 5718 | Board Member | 1 | $0 |
| Joel S Marcus Start 32918 | Board Member | 1 | $0 |
| Claudia S Luttrell | Board Member (Start 3/29/18) | 1 | $0 |
| Ge Li Start 32918 | Board Member | 1 | $0 |
| Sherry Lansing Start 5718 | Board Member | 1 | $0 |
| Jeffery Kelly Start 92818 | Board Member | 1 | $0 |
| William R Hearst Iii | Board Member (Start 3/29/18) | 1 | $0 |
| Benedict Gross Start 92818 | Board Member | 1 | $0 |
| Isy Goldwasser | Board Member | 1 | $0 |
| Peter C Farrell Phd Dsc | Board Member (Start 3/28/18) | 1 | $0 |
| Mark Edwards | Board Member | 1 | $0 |
| John D Diekman Start 32918 | Board Member | 1 | $0 |
| Gerald Chan Start 32918 | Board Member | 1 | $0 |
| Ronald Burkle | Board Member | 1 | $0 |
| Herbert Boyer | Board Member | 1 | $0 |
Data for this page was sourced from XML published by IRS (
public 990 form dataset) from:
https://s3.amazonaws.com/irs-form-990/201932269349300043_public.xml